Anti-flu peptides could become handy when vaccines are unavailable, in the case of a new pandemic strain, or
when circulating strains become resistant to current drugs, says senior author Joshy Jacob, PhD, associate professor of microbiology and immunology at Emory Vaccine Center and Emory University School of Medicine.
Not exact matches
«Even
when the vaccine is not a perfect match to the
circulating influenza
strain, as is the case this year, the vaccine still helps prevent more severe infections if children get sick with the flu,» she says.
However, even in previous years
when the vaccine has been well - matched to
circulating influenza
strains, effectiveness has been low (40 to 60 percent).
It is well - established that influenza vaccines are less effective in «mismatched» seasons
when the main
circulating strains change after the months - long vaccine production process has already begun.
So H1N1 in itself is a, you know, broad category of viruses that
circulate in humans, even now; they are not as fearsome as the original
strain when it first emerged.
These rare VDPVs arise
when a virus used in the live vaccine reverts from its weakened form and regains its virulence — a danger
when vaccination rates are low, as they are in both places, allowing the vaccine
strain to
circulate and accumulate genetic mutations.